Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
Zou J, Li L, Zheng P, Liang W, Hu S, Zhou S, Wang Y, Zhao J, Yuan D, Liu L, Wu D, Xu M, Zhang F, Zhu M, Wu Z, Cao X, Ni M, Ling X, Wu Y, Kuang Z, Hu M, Li J, Li X, Guo X, Xu T, Jiang H, Gao C, Yu M, Liu J, Zhong N, Zhou J, Huang JA, Jin T, He J.
Zou J, et al.
J Clin Invest. 2022 Feb 15;132(4):e154987. doi: 10.1172/JCI154987.
J Clin Invest. 2022.
PMID: 35108220
Free PMC article.